Why the study?
The role of PCSK9 in predicting major adverse cardiovascular events in NSTEMI patients remains an open question, and the clinically useful concentration to guide treatment is unknown.
Do high baseline plasma PCSK9 levels predict major adverse cardiovascular events in patients with NSTEMI undergoing PCI?
Do high baseline plasma PCSK9 levels predict major adverse cardiovascular events in patients with NSTEMI undergoing PCI?
High baseline PCSK9 levels independently predict future major adverse cardiovascular events in NSTEMI patients undergoing PCI, particularly those with high GRACE scores.
Answers are grounded in this paper and cite their sources.
High PCSK9 may refine post-PCI risk assessment in NSTEMI; leaves open causal role and therapeutic implications.
BACKGROUND: The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in predicting major adverse cardiovascular events (MACEs) in Non-ST elevation myocardial infarction (NSTEMI) patients is still an open question, and the PCSK9 concentration of clinical usefulness remains unknown in guiding treatment. METHODS AND RESULTS: A total of 272 patients with NSTEMI were included in our prospective observational cohort study. Patients were followed up for 1 year. Their baseline plasma PCSK9 levels were determined by enzyme-linked immunosorbent assay. Patients were divided into high, medium, and low PCSK9 groups. All patients followed up for the occurrence of MACEs and received PCI therapy after admission. The associations of PCSK9 with MACEs were evaluated. The results showed that the incidence of composite MACEs was greater at higher concentrations of PCSK9. PCSK9 level was related to the level of lipoproteins, high-sensitivity C-reactive protein (hs-CRP), platelet volume distribution width, and D-Dimer. There was also a statistically significant correlation between PCSK9 concentrations and the GRACE score. The Kaplan-Meier curves showed that patients with high PCSK9 level had lower event-free survival rate. The survival analysis indicated high level of PCSK9-predicted MACEs independently. Subgroup analysis demonstrated that the prognostic value of high PCSK9 level was greater for patients classified by the GRACE score as high risk. CONCLUSION: In an NSTEMI setting, the concentration of PCSK9 is associated with hypercoagulability and hyperinflammation. High levels of PCSK9 independently predict future MACEs in patients with NSTEMI, particularly those classified by the GRACE score as high risk.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: